)
Celldex Therapeutics (CLDX) investor relations material
Celldex Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Barzolvolimab phase III results
Phase III CSU results showed complete response in a majority of patients, prospective angioedema clearing at 12 weeks, and similar responses in omalizumab-refractory patients.
One regimen requires seven dosing days per year; HCPs highlighted rapid, durable responses that deepen over time, severe disease with angioedema, and biologic-refractory patients as key differentiators.
Phase II follow-up showed 41% of patients remained in complete response seven months after their last dose; phase III off-therapy durability data will follow treatment through 52 weeks and subsequent follow-up.
The overall safety profile was described as favorable; common KIT-mediated adverse events were mostly mild to moderate and expected to reverse, while serious and grade 3/4 event rates matched placebo.
Two phase III cases were adjudicated as probable anaphylaxis, both after the first barzolvolimab dose; a separate adjudicated anaphylaxis case occurred on placebo.
Regulatory and data milestones
BLA submission is guided for 2027, using the full 52-week data; the goal is to bring the therapy to patients as quickly as possible.
At AAAAI in February 2027, the planned presentation will cover 24-week efficacy, including primary and key secondary endpoints, 12- and 24-week results, and time course.
Additional presentations on secondary and exploratory endpoints are planned in the coming months; phase III off-therapy follow-up will come after the 52-week treatment period.
CIndU phase III trials are enrolling; further guidance is expected in the next few months. Atopic dermatitis data are expected by year-end, from a moderately severe population that allows prior therapies, including biologics.
Market and commercialization
In the U.S., an estimated 30% of CSU prevalence is diagnosed, and fewer than 20% of diagnosed patients clinically eligible for advanced therapy receive one.
Barzolvolimab is positioned for first-line patients with severe disease or angioedema, estimated at at least 25% of first-line patients, and as a second-line option for patients with ongoing symptoms.
Other therapies have complete response rates of 30%–38%; one-year real-world attrition for patients starting omalizumab or dupilumab is 50%, supporting a substantial second-line opportunity.
Preliminary payer discussions support a premium, value-based pricing strategy; commercial preparations include expanding the MSL team and building market analytics, brand, and payer teams.
Payer exchange under PIE is anticipated in H1 2027; infrastructure development is described as disciplined, data-based, milestone-driven, and focused on high-value prescriber accounts.
- Phase 3 CSU success supports a 2027 BLA, backed by $650.3M in liquidity.CLDX
Q3 2026 - Barzolvolimab achieved rapid, durable efficacy and safety in severe, refractory CSU, meeting all endpoints.CLDX
Study result - Barzolvolimab's phase III data and commercial plans highlight innovation in advanced urticaria therapy.CLDX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Barzolvolimab delivers rapid, durable efficacy in CSU, with major data milestones expected in 2026.CLDX
Corporate presentation - Q2 2026 net loss rose 30% as R&D spending surged, but liquidity remains strong through 2028.CLDX
Q2 2026 - No efficacy seen in prurigo nodularis; program discontinued, safety profile remains favorable.CLDX
Study result - Phase 2 and 52-week data in CSU and CIndU drive phase 3 launches and broad clinical expansion.CLDX
Guggenheim Securities Inaugural Healthcare Innovation Conference - All proposals passed, with strong financials and pipeline progress highlighted.CLDX
AGM 2026 - Barzolvolimab showed rapid, significant disease control in CIndU and is advancing to Phase 3.CLDX
Status Update
Next Celldex Therapeutics earnings date
Next Celldex Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)